Table 2.

Cox regression analysis for estimating prediction markers of progression-free and overall survival.

Variables		Progression-free survival
		Univariate analysis			Multivariate analysis
		HR.	95% CI	P-value	HR.	95% CI	P-value
Gender	Male vs. Female	0.800	0.473-1.354	0.407
B2M	Normal vs. Elevated	3.574	2.081-6.139	<0.001	1.965	1.039-3.718	0.038
LDH	Normal vs. Elevated	2.923	1.718-4.973	<0.001
CNS involved	Involved vs. Not involved	11.843	6.873-20.406	<0.001	8.674	4.777-15.749	<0.001
Stage	I/II vs. III/IV	5.647	2.928-10.892	<0.001	3.436	1.333-8.858	0.011
IPI	<2 vs. ≥ 2	4.349	2.303-8.215	<0.001
COO	GCB vs. non-GCB	0.875	0.605-1.267	0.480
sMICA	Detection vs. Not detection	2.091	1.221-3.584	0.007
sMICB	Detection vs. Not detection	1.746	1.041-2.926	0.035
TNF-α	Detection vs. Not detection	1.892	1.101-3.252	0.021
IL-1RA	Detection vs. Not detection	1.869	1.115-3.133	0.018
IL-10	Detection vs. Not detection	2.030	1.161-3.548	0.013
Variables		Overall survival
		Univariate analysis			Multivariate analysis
		HR	95% CI	P-value	HR	95% CI	P-value
Gender	Male vs. Female	0.834	0.387-1.798	0.644
B2M	Normal vs. Elevated	3.499	1.530-7.998	0.003
LDH	Normal vs. Elevated	5.661	2.284-14.032	<0.001
CNS involved	Involved vs. Not involved	5.002	2.288-10.935	<0.001	3.067	1.301-7.231	0.010
Stage	I/II vs. III/IV	5.252	1.988-13.870	0.001
IPI	<2 vs. ≥ 2	5.951	2.058-17.211	0.001
COO	GCB vs. non-GCB	0.814	0.464-1.427	0.473
sMICA	Detection vs. Not detection	1.825	0.828-4.021	0.136
sMICB	Detection vs. Not detection	2.062	0.964-4.411	0.062
TNF-α	Detection vs. Not detection	2.756	1.165-6.519	0.021
IL-1RA	Detection vs. Not detection	1.511	0.706-3.232	0.287
IL-10	Detection vs. Not detection	1.700	0.744-3.886	0.209

sMICA, soluble major histocompatibility complex class I-related chain A; sMICB, soluble major histocompatibility complex class I-related chain B; P, P-value; ECOG, European Cooperative Oncology Group; PS, Performance status; LDH, Lactate dehydrogenase; COO, Cell-of-origin; IPI, International prognostic index.